Clinical Trial Update: ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems [Phase 1]

View source ↗

Summary

Phase 1 trial of ABT-888 (veliparib) with carboplatin and paclitaxel for cancer patients with liver or kidney impairment has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• ABT-888 (veliparib)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms | Phase 1 | Status: WITHDRAWN